---
document_datetime: 2023-09-21 19:13:14
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/osigraft-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: osigraft-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.1315695
conversion_datetime: 2025-12-19 00:37:46.728505
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Osigraft

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                   | Opinion/ Notification 1 issued on on no   | Commission Decision Issued 2 / amended   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|------------------------------------------|----------------------------------|-----------|
| IG/0474              | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location product | 02/09/2014                                | n/a                                      |                                  |           |
| IG/0473/G            | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH                                           | 22/08/2014                                |                                          | SmPC, Annex II, Labelling and PL |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|
| WS/0421/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised Medicinal product | 25/04/2014 | n/a no     | longer authorised |
| WS/0452   | This was an application for a variation following a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/02/2014 | 10/03/2014 | Annex II and PL   |

<div style=\"page-break-after: always\"></div>

|             | worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. New manufacturing site for quality control and release testing of the finished product. B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method   |               | authorised                               |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------------------------------------|
| IG/0411/G   | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                 | 18/02/2014 no | 10/03/2014 SmPC, Labelling and PL longer |
| IAIN/0073/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing Medicinal product           | 01/10/2013    | n/a                                      |
| WS/0364/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                  | 19/09/2013    | n/a                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Change to drug substance and finished product quality control methods. Approval of additional drug substance control testing site. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   | product no   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| WS/0406   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Extension of drug substance shelf life. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                    | 25/07/2013   |
| IAIN/0072 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 24/07/2013   |

<div style=\"page-break-after: always\"></div>

| WS/0395/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Deletion of manufacturing site. Changes to manufacturing process. A.7 - Administrative change - Deletion of manufacturing sites B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 27/06/2013    | n/a authorised   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------------|
| WS/0387/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Addition of quality control testing laboratory. Changes to test method and acceptance criteria. Extension of excipient shelf life. B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or Medicinal product | 27/06/2013 no | n/a longer       |

<div style=\"page-break-after: always\"></div>

|           | addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |               |                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-----------------|
| IB/0067   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Extension of storage period of a biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/01/2013 | 10/03/2014    | SmPC authorised |
| IA/0066/G | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer product | 15/10/2012 | n/a no longer |                 |
| IB/0065/G | This was an application for a group of variations. B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) Medicinal                                                                                                                                                                                                                                                                           | 02/08/2012 | n/a           |                 |

<div style=\"page-break-after: always\"></div>

| WS/0224/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products. B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                         | 15/03/2012    | n/a authorised      |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------------------|
| IA/0064/G   | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.c.z - Change in control of excipients in the Finished Product - Other variation Medicinal product | 29/02/2012 no | n/a Annex II longer |

<div style=\"page-break-after: always\"></div>

| WS/0203/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)   | 16/02/2012         | 16/02/2012   |                                         | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0056/G   | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                                         | 20/10/2011         | n/a no       | SmPC, Annex II, Labelling and PL longer |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| T/0055      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                     | 05/07/2011 product | 24/08/2011   | SmPC, Annex II, Labelling and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| R/0053      | Renewal of the marketing authorisation. Medicinal                                                                                                                                                                                                                                                                                                                                                                       | 17/02/2011         | 02/05/2011   | SmPC, Annex II, Labelling and PL        | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of Osigraft continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Osigraft continues to be favourable. The CHMP recommends the renewal of the Marketing Authorisation with unlimited validity. |

<div style=\"page-break-after: always\"></div>

| IA/0054   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 23/03/2011   | n/a           | Annex II and PL   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-------------------|
| WS/0077/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Minor changes to an approved test procedures for an excipient and of the finished product. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 17/03/2011   | 17/03/2011 no | longer authorised |
| WS/0064/G | procedure This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes in the manufacturing process of the active substance. Change in the specification parameters of the active substance. Minor changes in test procedure for active substance. Submission of an updated Ph. Eur. Certificate of suitability. Medicinal product                                                                                                                                                                                                                                        | 17/03/2011   | 17/03/2011    |                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer   | longer                   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| WS/0057 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change in test procedure for active substance - Addition of new reference standards. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS Medicinal product                                                                                                                                                                                              | 20/01/2011 20/01/2011 no |
| WS/0050 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21/10/2010 21/10/2010    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | Change to the in-process limits during the manufacture of the active substance. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                | authorised                      |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| IB/0051 | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH | 28/07/2010 n/a SmPC and         |
| II/0050 | Updates to release specifications and changes to end-of-shelf-life specifications. Change(s) to the test method(s) and/or specifications for the finished product                                                                                          | 22/04/2010 28/04/2010 no longer |
| II/0048 | Updates to the excipient (collagen matrix) including a new manufacturing suite and a scaled up process. Change(s) to the manufacturing process for the finished product product                                                                            | 18/03/2010 24/03/2010           |
| II/0045 | Updates to the auditing of the sterilization process. The terminal sterilisation process used during routine production remains unchanged. Change(s) to the manufacturing process for the finished product Medicinal                                       | 22/10/2009 30/10/2009           |

<div style=\"page-break-after: always\"></div>

| IB/0046   | IB_36_a_Change in shape or dimensions of the container/closure - sterile ph. forms/biologicals                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 20/07/2009    | n/a                   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-----------------------|
| II/0044   | Changes to module 3 (analytical methods, specifications, stability protocol) in order to comply with post-authorisation commitments. Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                                                                    | 25/06/2009    | 02/07/2009 authorised |
| II/0043   | The applicant updated the Module 3 information for Osigraft to align it with the recently approved dossier for Opgenra. Some specifications of the active substance, finished product and excipients has been updated. Also minor updates to the manufacturing process of the active substance and finished product have been introduced. Update of or change(s) to the pharmaceutical documentation Change(s) to the manufacturing process for the active substance Change(s) to the manufacturing process for the finished product Change(s) to the test method(s) and/or specifications product | 23/04/2009 no | 28/04/2009 longer     |
| IA/0042   | IA_28_Change in any part of primary packaging material not in contact with finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 09/10/2008    | n/a                   |
| IA/0041   | for the active substance IA_05_Change in the name and/or address of a manufacturer of the finished product Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 02/10/2008    | n/a                   |

<div style=\"page-break-after: always\"></div>

| II/0040   | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                         | 25/09/2008   | 01/10/2008    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0039   | IA_16_b_Submission of new TSE certificate relating to active substance - other substances                                                                                                                                                                                                               | 20/05/2008   | n/a           |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0038   | To update sections 4.4 and 4.5 of the SPC to include that the use of Osigraft with synthetic bone void filler is not recommended, as requested by the CHMP following the assessment of PSUR No 8. The PL has been updated accordingly. Update of Summary of Product Characteristics and Package Leaflet | 21/02/2008   | 02/04/2008    | SmPC and PL longer     | During the period covered by PSUR No 8 (from 1 October 2005 to 30 September 2006) an increased trend in adverse events associated with the use of a synthetic bone void filler was noted. The adverse events reported included localised induration, swelling, inflammation, wound drainage, infection and device migration. Seven of the events required surgical intervention. Thus, sections 4.4 and 4.5 of the SPC were updated to include that the use of Osigraft with synthetic bone void filler is not recommended as post-marketing surveillance data have shown an increase in local inflammation, infection and occasional migration of the implanted materials. authorised |
| II/0034   | Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                                                         | 24/01/2008   | 29/02/2008 no | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0036   | Change(s) to the test method(s) and/or specifications for the finished product product                                                                                                                                                                                                                  | 24/01/2008   | 05/02/2008    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0037   | Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                                                                                                                          | 20/09/2007   | 25/09/2007    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0033   | To remove \"pregnancy\" from section 4.3 and to update sections 4.6 and 5.3 of the SPC to include additional information on formation of anti-osteogenic protein-1 antibody following new non-clinical data. To update section 4.4 of the SPC to include that the Medicinal                               | 22/03/2007   | 02/05/2007    | SmPC, Labelling and PL | The MAH has studied the impact of immunogenicity of eptotermin alfa (OP-1) during repeated administration in non-clinical studies and the toxic effects of anti-OP-1 antibodies on pre- and post-natal development, including maternal function, in non-clinical study in rabbits.                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

repeated use of Osigraft cannot be recommended due the results of cross-reactivity studies with anti-osteogenic protein-1 antibodies. These changes were requested by the CHMP on the 27 of July 2006 following the assessment of FUM 001 on immunogenicity. Section 2 of the PL was updated accordingly to reflect the changes introduced in the SPC. The MAH took the opportunity to introduce some minor editorial changes to the labelling.

Update of Summary of Product Characteristics, Labelling and Package Leaflet

These non-clinical studies have produced information on the potential risks of OP-1 and the impact on experimental anti-OP-1 on foetal development. The results from these new non-clinical studies were reassuring in terms of the interference of growth factor-antibodies with foetal development. As the basis for a contraindication must be provided by clinical data or strong non-clinical data, the CHMP concluded that there was no basis for a contraindication of the use of Osigraft during pregnancy. Thus, the contraindication for pregnancy was removed from section 4.3 \"Contraindication\" of the SPC and replaced by an advice not to use Osigraft during pregnancy in section 4.6 \"Pregnancy and lactation\" unless the potential benefit justifies the potential risks to the foetus. In addition, women of childbearing potential should be advised to use effective contraception up to at least 12 months after treatment.

As the excretion of IgG class anti-OP-1 antibodies into milk has been observed in these non-clinical studies, and the potential for harm to the infant is unknown, the CHMP concluded that women should not breast-feed during Osigraft therapy.

As anti-OP-1 antibodies have the ability to neutralise the in vitro biological activity of Bone Morphogenic Proteins (BMPs), the CHMP acknowledged that upon re-administration of Osigraft, a risk of developing autoimmunity towards the endogenous BMPs may exist. Thus, section 4.4 \"Special warnings and precautions for use\" of the SPC was updated to include that the repeated use of Osigraft cannot be recommended.

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                              |                    |               |                                  | The results of these new non-clinical studies have been included in section 5.3 \"Preclinical safety data\" of the SPC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0035 | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                   | 22/02/2007         | 27/02/2007    |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0032 | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                               | 14/12/2006         | 18/12/2006    |                                  | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0031 | This variation is to introduce additional manufacturing areas for the drug substance and the bone powder in the currently approved facility. Change(s) to the manufacturing process for the active substance | 19/10/2006         | 24/10/2006    | longer                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0028  | Renewal of the marketing authorisation. Medicinal                                                                                                                                                            | 23/03/2006 product | 19/05/2006 no | SmPC, Annex II, Labelling and PL | The exposure to Osigraft is still very limited and no new clinical studies have been reported requiring regulatory actions. Within the renewal application the MAH provided a review of published non-clinical and clinical studies. These studies pursued mainly new therapeutic applications and use with various antibiotics, fillers and devices. This review did not reveal any information that would have an impact on the product information. No new safety issues have emerged from the safety update included in the renewal submission. Non-clinical studies on potential carcinogenicity of eptotermin alfa (OP-1) were performed as follow up measures. Several cancer cell lines expressed OP-1 receptor and certain cancer cell lines proliferated upon exposure to OP-1. However, in vivo studies demonstrated differentiation rather than proliferation when OP-1 was used in nude mice bearing tumour cells. It was concluded that, for time being, there is no safety signal. In any case, the effect of OP-1 |

<div style=\"page-break-after: always\"></div>

## would be local and not systemic.

Immunological studies were conducted as follow up measures. The results demonstrated that patients may develop both IgM and IgG class antibodies to OP-1. These antibodies can cross-react with other bone growth/differentiation factors. The anti-OP-1 antibody response was boostered by repeated administration. The results demonstrate that there is a significant immune response associated with the use of OP-1, especially after re-treatment. For the time being, repeated use of Osigraft continues to be discouraged. The Product Information of Osigraft has been updated with regard to immunological findings in the context of a previously approved Type II variation.

Based upon the data that have become available since the granting of the initial Marketing Authorisation, the CHMP considered that the benefit-risk balance of Osigraft remains positive. However, as the exposure data with the product is very limited and several safety issues are under scrutiny, includi

| II/0027   | Change(s) to the manufacturing process for the finished product Change(s) to the test method(s) and/or specifications for the finished product   | 27/04/2006   | 03/05/2006   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|
| II/0026   | Update of or change(s) to the pharmaceutical documentation Change(s) to shelf-life or storage conditions Medicinal                               | 27/04/2006   | 03/05/2006   |
| II/0029   | Change(s) to the test method(s) and/or specifications                                                                                            | 23/02/2006   | 28/02/2006   |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|         | for the finished product                                                                                                                                                                                                                         |            |               |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0030 | IA_28_Change in any part of primary packaging material not in contact with finished product                                                                                                                                                      | 17/11/2005 | n/a           |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0025 | This variation relates to an update in section 4.4 in the SPC and section 2 in the PL with new findings on immunogenicity data and test for neutralizing antibodies. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 26/05/2005 | 28/06/2005    | SmPC, Labelling and PL | Antibodies to OP-1 protein (anti-Osteogenic protein 1) were detected in 66% of patients in the tibial non-union study following the administration of Osigraft. Analysis of these antibodies showed that 9% had neutralizing capacity. However, no association with clinical outcome or adverse event could be observed in clinical studies. These new findings on immunogenicity data and test for neutralizing antibodies have been included in the SPC and PL. Additionally, the SPC and PL have been amended to include that in the absence of any experience, the repeated use of Osigraft should be avoided. authorised |
| II/0023 | Quality changes                                                                                                                                                                                                                                  | 26/05/2005 | 02/06/2005 no | longer                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0022 | Change(s) to the manufacturing process for the active substance Change(s) to the test method(s) and/or specifications for the active substance product                                                                                           | 26/05/2005 | 02/06/2005    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0021 | Update of or change(s) to the pharmaceutical documentation Change(s) to the manufacturing process for the active substance Medicinal                                                                                                             | 16/09/2004 | 21/09/2004    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0020 | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                                                                   | 29/07/2004 | 02/08/2004    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0019 | Change(s) to the manufacturing process for the                                                                                                                                                                                                   | 29/07/2004 | 02/08/2004    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         | finished product                                                                                                            |            |               |                        |
|---------|-----------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|
| II/0018 | Change(s) to the manufacturing process for the finished product                                                             | 03/06/2004 | 08/06/2004    | authorised             |
| II/0017 | Change(s) to the test method(s) and/or specifications for the finished product                                              | 24/03/2004 | 30/03/2004    |                        |
| II/0015 | Update of or change(s) to the pharmaceutical documentation                                                                  | 20/11/2003 | 17/12/2003    |                        |
| I/0016  | 25_Change in test procedures of the medicinal product 27_Change in test procedures of non-pharmacopoeial excipients         | 17/11/2003 | 21/11/2003    | longer                 |
| II/0009 | Change(s) to the test method(s) and/or specifications for the finished product Update of Summary of Product Characteristics | 23/01/2003 | 08/04/2003 no | SmPC                   |
| I/0014  | 20_Extension of shelf-life as foreseen at time of authorisation                                                             | 17/10/2002 | 12/11/2002    | SmPC                   |
| I/0010  | 02_Change in the name of the medicinal product (either invented name of common name) product                                | 09/07/2002 | 03/10/2002    | SmPC, Labelling and PL |
| I/0013  | 24_Change in test procedure of active substance                                                                             | 02/08/2002 | 10/09/2002    |                        |
| I/0012  | 18_Synthesis or recovery of non-pharmacopoeial excipients in the medicinal products Medicinal                               | 02/08/2002 | 10/09/2002    |                        |
| I/0011  | 24_Change in test procedure of active substance                                                                             | 25/07/2002 | 31/07/2002    |                        |

<div style=\"page-break-after: always\"></div>

| I/0008   | 24_Change in test procedure of active substance                                                      | 17/01/2002   | 28/01/2002        |
|----------|------------------------------------------------------------------------------------------------------|--------------|-------------------|
| I/0007   | 19_Change in specification of excipients in the medicinal product (excluding adjuvants for vaccines) | 02/08/2001   | n/a               |
| I/0005   | 17_Change in specification of the medicinal product                                                  | 02/08/2001   | n/a authorised    |
| I/0001   | 31_Change in container shape                                                                         | 02/08/2001   | n/a               |
| I/0002   | 24_Change in test procedure of active substance                                                      | 26/07/2001   | 31/07/2001 longer |
| I/0006   | 19_Change in specification of excipients in the medicinal product (excluding adjuvants for vaccines) | 17/07/2001   | n/a               |
| I/0003   | 19_Change in specification of excipients in the medicinal product (excluding adjuvants for vaccines) | 17/07/2001   | n/a               |

Medicinal product no longer authorised